Want to see SG:42C full AI Analyst Report?
iX Biopharma Ltd. (42C) Income Statement
iX Biopharma Ltd. Income Statement
Last quarter (Q4 2025), iX Biopharma Ltd.'s total revenue was $5.26M, an increase of 60.15% from the same quarter last year. In Q4, iX Biopharma Ltd.'s net income was $-7.08M. See iX Biopharma Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| $ 6.85M | $ 7.77M | $ 5.96M | $ 5.91M | $ 14.39M | |
| $ 2.43M | $ 2.04M | $ 1.05M | $ 2.32M | $ 12.29M | |
| $ 11.99M | $ 8.32M | $ 8.44M | $ 10.73M | $ 11.05M | |
| Depreciation and Amortization | $ 728.00K | $ 854.00K | $ 868.00K | $ 929.00K | $ 1.06M |
| $ -8.83M | $ -8.96M | $ -8.68M | $ -8.51M | $ -2.84M | |
| $ -9.56M | $ -6.29M | $ -7.39M | $ -8.41M | $ 1.24M | |
| $ 1.58M | $ -3.85M | $ -2.60M | $ -1.29M | $ -5.34M | |
| $ -7.98M | $ -10.14M | $ -9.98M | $ -9.71M | $ -4.10M | |
| $ -7.99M | $ -10.14M | $ -10.79M | $ -9.62M | $ -4.60M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.01 | $ -0.01 | $ -0.01 | $ -0.01 | $ -0.01 |
| Diluted EPS | $ -0.01 | $ -0.01 | $ -0.01 | $ -0.01 | $ -0.01 |
| Weighted Average Shares Outstanding | 965.01M | 874.22M | 767.36M | 764.85M | 754.63M |
| Weighted Average Shares Outstanding (Diluted) | 965.01M | 876.68M | 767.36M | 764.85M | 754.63M |
Currency in SGD
